Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.
I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...
The latest chemistry news, including important research advances, business and policy trends, chemical safety practices, career guidance, and more. Current approved CAR T-cell therapy treatments rely ...
MedPage Today on MSN
CAR T-cell trial in rheumatoid arthritis starts off strong
Strong initial responses in 4 of 6 patients after many standard drugs had failed ...
Legend Biotech (LGND) stock jumps as the company posts early-stage trial data for in vivo CAR-T cell therapy in B-cell ...
PeproMene Bio, Inc. announced today that updated clinical data from its ongoing Phase 1 study evaluating PMB-CT01, an investigational B-cell activating factor receptor (BAFF-R)-targeted CAR T-cell ...
Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare. Recent anecdotal reports suggest ...
Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without laboratory cell manufacturing and ex vivo expansion. The method using targeted ...
CAR T-cell therapy has the potential to revolutionise how we treat certain types of cancer by genetically engineering someone’s own immune cells to attack the disease – but it is also cumbersome and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results